Timber Pharmaceuticals, Inc. - TMBR STOCK NEWS

Timber Pharmaceuticals, focused on rare dermatologic diseases, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. An on-demand corporate presentation will be available starting September 13 at 7:00 am ET. The slide presentation can be accessed on the company’s website. CEO John Koconis and CFO Joe Lucchese will also hold one-on-one meetings with registered investors. Timber is committed to developing treatments for conditions such as congenital ichthyosis and facial angiofibromas.

Timber Pharmaceuticals (TMBR) has announced the completion of patient visits in the Phase 2b CONTROL study for TMB-001, a topical isotretinoin treatment for congenital ichthyosis. This milestone brings the company closer to reporting topline data expected in Q4 2021 and planning for an End-of-Phase 2 meeting with the FDA. The study involved 34 patients and aims to improve treatment for this rare genetic skin disorder. TMB-001's delivery system aims to enhance isotretinoin absorption while minimizing systemic effects.

Timber Pharmaceuticals (TMBR) provided a business update and Q2 financial results for the quarter ending June 30, 2021. The Phase 2b CONTROL study for lead asset TMB-001 in Congenital Ichthyosis completed recruitment with 34 patients, expecting results in Q4 2021. TMB-002's trial for facial angiofibromas has surpassed 50% recruitment, aiming for completion by Q3 2021. The company recognized $388,819 in revenue from FDA reimbursements and a licensing milestone. Cash reserves stood at $6.1 million at quarter's end.

Timber Pharmaceuticals, Inc. (TMBR) announced that the 2021 Annual Meeting of Stockholders was convened without a quorum on June 3, 2021, leading to its adjournment. The meeting is rescheduled for July 1, 2021, at 1:00 p.m. ET, allowing shareholders more time to vote. The record date remains April 12, 2021. Timber Pharmaceuticals focuses on developing treatments for rare dermatologic diseases, including congenital ichthyosis and scleroderma.

Timber Pharmaceuticals (TMBR) is nearing the completion of patient enrollment in its Phase 2b CONTROL study for TMB-001, targeting moderate to severe congenital ichthyosis (CI). The company plans to request an end-of-Phase 2 meeting with the FDA by the end of 2021, supported by positive data from its Phase 2a program. CI is a rare skin disorder with significant unmet treatment needs. Timber expects to release top line results from the Phase 2b study in Q4 2021, following early enrollment closure aimed at expediting progress to Phase 3 trials.

Timber Pharmaceuticals (TMBR) provided a business update and financial results for Q1 2021, highlighting advancements in its clinical programs. The Phase 2b CONTROL Study of TMB-001 for Congenital Ichthyosis has reached 50% enrollment, with topline data expected in Q3 2021. Significant progress was also reported for TMB-002, with a licensing agreement in Europe that benefits Timber through royalties. Additionally, TMB-003 received orphan drug designation from the FDA. As of March 31, 2021, the company had $8.5 million in cash and 36.7 million shares outstanding.

Timber Pharmaceuticals (TMBR) announced the Japanese Patent Office has granted a patent for TMB-001, a topical isotretinoin formulation targeted at treating moderate to severe congenital ichthyosis (CI). This milestone follows similar patent allowance in the U.S. The company, focusing on rare dermatologic conditions, is advancing its Phase 2b CONTROL study for TMB-001, which assesses safety and efficacy in various concentrations. In 2018, TMB-001 received a $1.5 million FDA grant to support its clinical trials.

Timber Pharmaceuticals has announced significant leadership changes, appointing John Koconis as Chairman of the Board while retaining his role as CEO. Edward J. Sitar has been named Lead Independent Director, and Dr. David Cohen will chair a new Science and Technology Committee. The company is advancing its clinical research on rare dermatologic diseases like congenital ichthyosis and scleroderma.

Timber Pharmaceuticals (TMBR) announced its Annual Meeting of Shareholders will occur on June 3, 2021, with April 12, 2021, set as the record date. Shareholders will receive meeting materials around April 23, 2021. The company also disclosed that its audited financial statements for 2020 include a 'going concern' emphasis from its auditors, highlighting potential uncertainties affecting its future operations. This announcement aligns with NYSE American regulations, underscoring the financial scrutiny Timber faces.